Milestone Scientific expects Q2 revenue of ~$2.8M, up 21% YoY
Milestone Scientific Inc. announced preliminary unaudited revenue for Q2 2026 of approximately $2.8 million, a 21% increase from the prior year, with H1 revenue rising 9% to $5.0 million. Growth was led by a 300% surge in the medical segment and international expansion, alongside progress in reimbursement claims.
*this image is generated using AI for illustrative purposes only.
Milestone Scientific Inc. expects preliminary unaudited revenue for the second quarter ending June 30, 2026, of approximately $2.8 million, representing a 21% increase compared to $2.3 million for the same period in 2025. For the six months ending June 30, 2026, the company anticipates total revenue of approximately $5.0 million, a 9% increase compared to $4.5 million in the prior year. The medical segment drove growth with a 300% revenue increase in the second quarter compared to the second quarter of 2025.
Eric Hines, Chief Executive Officer of Milestone Scientific, attributed the performance to continued execution of core business initiatives and penetration of key international markets. The base business contributed approximately $2.4 million in revenue for the quarter, bolstered by approximately $500,000 from international orders. Hines noted significant progress on the reimbursement front, with 100 claims submitted successfully and the first successful paid workers' compensation claim.
The company plans to showcase its technology at the American Society of Pain & Neuroscience Conference in Miami Beach from July 16–18. Dr. Dawood Sayed, Vice Chairman and Co-Founder of ASPN, will attend. The company anticipates releasing full financial results and hosting a conference call in August 2026.
Preliminary Financial Performance
| Period | Revenue (Approx.) | YoY Change |
|---|---|---|
| Q2 2026 | $2.8 million | +21% |
| Q2 2025 | $2.3 million | - |
| 1H 2026 | $5.0 million | +9% |
| 1H 2025 | $4.5 million | - |
Segment and Operational Highlights
The medical segment's 300% growth reflects validation of the technology's value proposition, though it is growing from a small base. The dental business continues to expand internationally, with recent approval in Uzbekistan and planned registrations in Japan, Mexico, Turkey, and India in the coming quarters. The company expects commercialization initiatives to scale and contribute more meaningful revenue later in the year.
How will the successful processing of the first workers' compensation claim influence the speed and volume of future insurance reimbursements?
What specific revenue impact does Milestone Scientific anticipate from the planned commercialization initiatives in Japan, Mexico, Turkey, and India?
Can the medical segment sustain its triple-digit growth rate as it scales from a small base throughout the remainder of 2026?
20
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
